Artificial intelligence accelerates the development of medicine and health, and Beijing leads the way in the AI industry
The total amount of financing in the field of artificial intelligence in Beijing hits a new high
In recent years, with the rapid accumulation and development of data and computing power, artificial intelligence technology is accelerating the penetration and integration of traditional industries such as medical and health care, life services, and drug research and development. Impact.
On the eve of the opening of the 2022 Zhongguancun Forum, a reporter from Beijing Youth Daily visited representative companies in high-end industries such as Keya Medical Technology, Beijing Questyle Technology and Boya Jiyin (Beijing) Technology, and explained in detail how a series of technological innovation enterprises in Beijing The development of intelligent technology.
Innovative projects put into clinical practice
Served more than 4000 patients
Founded in January 2016, Keya Medical is the first Chinese AI medical device Class III certified enterprise, and is currently the only international leading enterprise in artificial intelligence medical care in the world that has triple-certified products of China NMPA, US FDA, and EU CE. The R&D team has more than 160 top industry experts.
"In the past, doctors needed to determine whether a patient had obstructive coronary heart disease, whether it should be done with cardiac stents, bypass surgery or more suitable for conservative drug treatment, and often needed to perform coronary angiography to determine preoperatively. Accept coronary angiography Patients undergoing angiography need to be hospitalized and then enter the catheterization room, where various instruments are inserted from the patient's radial artery to the coronary artery, and performed under the rays. It costs about 5,000 yuan. Now, in Anzhen Hospital, this examination can assist doctors to make corresponding judgments only through CT images, and patients only need to spend less than 2,000 yuan for this examination. Now we use our manual The intelligent system can analyze the whole by taking a CT scan, which not only relieves the trauma and pain for the patient, but also reduces the cost from the original 20,000 yuan to less than 2,000 yuan, which is less than 1/10 of the original." Keya Medical is responsible for people said.
"In August last year, the blockbuster innovative project introduced by Anzhen-Keya Medical-Enterprise Joint Laboratory - Non-invasive Coronary Fractional Flow Reserve Measurement (Deep Pulse Fractional DVFFR) was officially put into clinical use in Beijing Anzhen Hospital. The technology has served 4,254 patients in Anzhen Hospital, and a total of more than 1,000 patients have avoided coronary angiography examinations, saving patients about 20 million yuan in medical expenses.”
Anzhen-Keya Medical-Enterprise Joint Laboratory is mainly engaged in clinical application fields such as artificial intelligence technology, big data analysis and application, medical image analysis, surgical robot, precision medicine, clinical auxiliary diagnosis and treatment, pathological auxiliary diagnosis, early tumor screening and diagnosis and treatment. Innovative research.
AI builds a "brain" for the park
Improve comprehensive management efficiency
The artificial intelligence technology company "Megvii Technology" is located in the "BBMG Intelligent Manufacturing Factory" in Xisanqi, Haidian District.
It used to be an old and idle furniture factory.
Megvii has reached a cooperation with BBMG Group, taking "one park, one policy" as the main principle, and started to implement the further intelligent upgrading of BBMG Intelligent Manufacturing Workshop.
At present, in areas that are invisible to employees, Kuang has established a unified park brain for BBMG Intelligent Manufacturing Factory, which manages all aspects of the operation of the park.
The brain of the park realizes the connection of 16 subsystems including energy consumption, comprehensive security content, parking and catering, etc. AI cameras view the information of the park in real time, realize the structured processing of data, and can set alarm rules and automatically trigger notifications. Related personnel.
And this information will be visualized by a large screen 3D to restore the scene in the park, so that a large screen can manage the entire park.
The unified management brings about the improvement of the overall efficiency of the park.
In terms of efficiency improvement, AI cameras can view the information of the park in real time, realize the structured processing of data, and set alarm rules and automatically trigger to notify relevant personnel.
In the exhibition hall of Megvii Technology, it also displayed proven AIoT products and solutions for the three core scenarios of consumer IoT, urban IoT and supply chain IoT.
The most notable thing is that users can directly swipe their face to pass through the building gate, and simultaneously realize functions such as temperature measurement, code scanning, nucleic acid vaccine inspection, mask wearing, identity verification and access control. This is the self-developed Megvii Shenxing epidemic prevention. Guards, users can swipe their faces, ID cards or QR codes to verify entry into the venue.
This system has good temperature measurement accuracy, supports nucleic acid overdue reminders, and supports data storage of hundreds of thousands of people, with a maximum of 60 people passing through at high speed in one minute.
Fu Yingbo, president of Megvii, told the Beiqing Daily reporter: "Megvii is one of the technological innovation enterprises in Zhongguancun, and has forged a deep bond with the Zhongguancun Forum. This is an international exchange and cooperation event that gathers cutting-edge technologies. For all science and technology enterprises, the Zhongguancun Forum is an excellent platform to demonstrate their capabilities and strengths, get close contact with the world's most sophisticated scientific and technological achievements, broaden their horizons of innovation, and promote industrial exchanges and cooperation." He also revealed that Megvii This year, we will deeply and comprehensively participate in multiple sections of the Zhongguancun Forum.
Thalassemia has an innovative treatment
Gene editing may cure patients
Boya Jiyin is a clinical-stage global biopharmaceutical company focusing on the transformation of gene editing technology. It is committed to developing innovative treatments for intractable genetic diseases and cancers.
Founded in 2015, Boya Jiyin is headquartered in Beijing, with offices in Guangzhou, Shanghai and the Greater Boston area of the United States. The scientific founder of the company is Professor Wei Wensheng of Peking University.
"The human genome contains about 3 billion DNA base pairs, so when a gene in a certain place is broken, how do we fix it? For example, these patients with beta thalassemia, their parents may each have a bad gene The hemoglobin gene has been changed, so the parents are basically fine, but after they get married, there is a 1/4 chance of giving birth to such a child, and severe patients may only have 5 years of life without any treatment.” CEO of Boya Jiyin Dr. Wei Dong told the Beiqing Daily reporter, "With the technology of gene editing, we can remove the patient's own hematopoietic stem cells, because we know where his gene is broken, and then put it back after repairing, so that If so, his reorganized blood system will be good, and the patient can be cured at one time, which is our goal."
In January 2021, BoyaGene's gene editing therapy product "ET-01" for transfusion-dependent beta-thalassemia became the first gene editing therapy product under development in my country that was approved by the State Food and Drug Administration for clinical trials.
At present, the multi-center Phase I clinical trial of ET-01 is being carried out in the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), the Southern Hospital of Southern Medical University, Shenzhen Children's Hospital and Guangzhou Women and Children's Medical Center, and has been completed All patients were enrolled.
Currently, Boyajiyin is based on four major therapeutic platforms. The company's product pipeline covers transfusion-dependent β-thalassemia, relapsed and refractory B-cell lymphoma and non-Hodgkin's lymphoma, optic neurodegenerative ophthalmic diseases, and relapsed and refractory advanced lymphoma. Disease areas such as rectal cancer and neurological diseases.
It has also reached research cooperation with leading institutions at home and abroad such as the University of Wisconsin-Madison and Peking Union Medical College Hospital to promote the development of innovative therapies.
Rapid growth of industry scale
A number of development indicators lead the country
As the first national new-generation artificial intelligence innovation and development pilot zone, Beijing has experienced rapid growth in its industrial scale and has formed a basically complete industrial chain. It is rapidly building an industrial ecosystem with global influence. The number of national new-generation artificial intelligence open innovation platforms, AI The number of scholars, the number of papers published and patent applications, the number of AI-related companies, the total amount of financing in the AI field, and the number of financing events are nationally leading.
On the whole, the artificial intelligence industry in Beijing continues to maintain a rapid growth trend and gradually becomes a new economic growth point in the capital.
According to incomplete statistics, the output value of artificial intelligence in 2021 will reach 207 billion yuan, a year-on-year increase of 11%; in 2022, Beijing's artificial intelligence-related output value is expected to be about 227 billion yuan, a year-on-year increase of 9.7%.
Beijing has built the first national new-generation artificial intelligence innovation and development pilot area, and the number of national new-generation artificial intelligence open innovation platforms leads the country; the number of scholars in the field of artificial intelligence exceeds 4,000, accounting for 28% of the country.
Beijing's core technical talents in the field of artificial intelligence exceed 40,000, accounting for 60% of the country's total. The number of AI scholars, AI industry talents, entrepreneurial talents and other dimensions are the first in the country, and the number of AI patent applications is the first in the country; Beijing artificial intelligence related enterprises The number exceeds 1,600, accounting for 28% of the total domestic artificial intelligence enterprises, ranking first in the country.
In addition, Beijing's investment in the field of artificial intelligence continues to lead the country.
In the whole year of 2021, there will be 359 artificial intelligence financing events in Beijing, a year-on-year increase of 25%; the total financing is 157.7 billion yuan, a year-on-year increase of 48%, a record high, and continues to rank first in the country.
Wen and photo / reporter Wen Jing co-ordinator / Chi Haibo